Public trial registry of the CCC-Munich

Trial 114-NH-301

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
114-NH-301
World
Full title
:

A phase III, randomized, double-blind study of galiximab in combination with rituximab compared with rituximab in combination with placebo for the treatment of subjects with relapsed or refractory, follicular Non Hodgkin's lymphoma.

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
KUM - Med3 - Medizinische Klinik und Poliklinik III Lmu
Indications
Classification Code Description
ICD-10-GM C81-C96 Bösartige Neubildungen des lymphatischen, blutbildenden und verwandten Gewebes, als primär festgestellt oder vermutet
Trial design
World
Trial type
:
Interventional
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Participants The lead of this trial has not explicitely given their approval for publishing the contact information of the principal investigators or specific contact persons.